Research Progress On The Necessity Of Antiviral Therapy For Chronic Hepatitis B Virus Carriers

Chronic hepatitis B virus carriers are facing the risk of progression of liver fibrosis, cirrhosis and hepatocellular carcinoma. However, the necessity of antiviral therapy in these patients still exisit controversy.Some people argue that the risk of the bad result is negligible, and the short term effect of antiviral therapy for chronic hepatitis B virus carriers is poor. But recent studies have clearly showed that the levels of ALT are unable to predict changes in liver tissue, liver fibrosis exist in almost half of HBV carriers, moreover, patients with high HBV DNA load, delayed HBV e antigen seroconversion have a high progress rate. They suggest that chronic hepatitis B virus carriers should be treated with antiviral therapy. The aim of this article is to summarizes the research status of chronic hepatitis B virus carriers, and its necessity and feasibility of antiviral therapy, to provide a theoretical basis for clinical practice.